OrganiGram Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OrganiGram stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGI, but not buy additional shares or sell existing shares.
View analyst ratings for OrganiGram or view top-rated stocks.

Wall Street analysts have given OrganiGram a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OrganiGram wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

OrganiGram saw a decline in short interest in March. As of March 31st, there was short interest totaling 11,710,000 shares, a decline of 17.5% from the March 15th total of 14,200,000 shares. Based on an average trading volume of 24,950,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 6.6% of the shares of the company are short sold.
View OrganiGram's Short Interest.

OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, July 20th 2021.
View our earnings forecast for OrganiGram.

OrganiGram Holdings Inc. (NASDAQ:OGI) posted its quarterly earnings data on Monday, April, 12th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.26. The firm earned $11.49 million during the quarter, compared to analysts' expectations of $15.70 million. OrganiGram had a negative net margin of 207.26% and a negative trailing twelve-month return on equity of 10.00%.
View OrganiGram's earnings history.

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OGI stock has increased by 53.5% and is now trading at $2.64.
View which stocks have been most impacted by COVID-19.

11 equities research analysts have issued 12 month target prices for OrganiGram's shares. Their forecasts range from $3.25 to $6.00. On average, they anticipate OrganiGram's stock price to reach $4.41 in the next year. This suggests a possible upside of 67.1% from the stock's current price.
View analysts' price targets for OrganiGram or view top-rated stocks among Wall Street analysts.

Some companies that are related to OrganiGram include Intra-Cellular Therapies (ITCI), Reata Pharmaceuticals (RETA), Arvinas (ARVN), Insmed (INSM), Taro Pharmaceutical Industries (TARO), PTC Therapeutics (PTCT), MorphoSys (MOR), Pacira BioSciences (PCRX), Rocket Pharmaceuticals (RCKT), Cryoport (CYRX), Amicus Therapeutics (FOLD), Zentalis Pharmaceuticals (ZNTL), ALX Oncology (ALXO), Corcept Therapeutics (CORT) and Global Blood Therapeutics (GBT).
View all of OGI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), (CGC), Auxly Cannabis Group (CBWTF), The Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), Cannabics Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

OrganiGram's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Swiss National Bank (0.18%), Vontobel Holding Ltd. (0.09%), BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp (0.09%), The Manufacturers Life Insurance Company (0.08%), Alberta Investment Management Corp (0.04%) and Commonwealth Equity Services LLC (0.03%).

OGI stock was sold by a variety of institutional investors in the last quarter, including Scotia Capital Inc., Sigma Planning Corp, and Creative Planning.

OGI stock was bought by a variety of institutional investors in the last quarter, including BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, The Manufacturers Life Insurance Company , Alberta Investment Management Corp, Commonwealth Equity Services LLC, Swiss National Bank, AE Wealth Management LLC, Telemus Capital LLC, and International Assets Investment Management LLC.

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OGI stock can currently be purchased for approximately $2.64.

OrganiGram has a market capitalization of $787.33 million and generates $64.61 million in revenue each year. The company earns $-101,290,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

OrganiGram employs 619 workers across the globe.

The official website for OrganiGram is www.organigram.ca.

OrganiGram is headquartered at 35 English Dr., Moncton Z4, E1E 3X3.

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.